 Home > Active Ingredient News > Immunology News > ARD: Tofacitinib and Risk of Cardiovascular Outcomes: Results of the Safety of Tofacitinib in Usual Care Patients with Rheumatoid Arthritis (STAR-RA) Study

ARD: Tofacitinib and Risk of Cardiovascular Outcomes: Results of the Safety of Tofacitinib in Usual Care Patients with Rheumatoid Arthritis (STAR-RA) Study

 Last Update: 2022-08-16
 Source: Internet
 Author: User

Tags

otg safety glasses

food safety policy

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Objectives: Recent results from the " ORAL Surveillance" trial have raised concerns about the cardiovascular safety of tofacitinib in patients with rheumatoid arthritis (RA.

Objectives: Objectives: Recent results from the " ORAL Surveillance" trial have raised concerns about the cardiovascular safety of tofacitinib in patients with rheumatoid arthritis (RA.

Methods Using claims databases from Optum Clinformatics ( 2012-2020 ), IBM MarketScan ( 2012-2018 ) , and Medicare ( Parts A , B , and D , 2012-2017 ) , two use cases were created using de-identified data Cohorts of RA patients treated with fatinib or a tumor necrosis factor inhibitor (TNFI) : (1) "Real World Evidence (RWE) cohort" of usual care patients and (2) Inclusion and exclusion of trials mimicking " ORAL surveillance" A standard "randomized controlled trial (RCT) -replicate cohort" trial to calibrate results to trial result.

Results In the RWE cohort, 102,263 patients were identified, of whom 12,852 ( 16% ) started tofacitin.

Conclusions This study found no evidence of an increased risk of cardiovascular outcomes in RA patients treated with tofacitinib in the real world ; however, in RA patients with cardiovascular risk factors, tofacitinib was associated with an increased risk of cardiovascular outcomes, although Not statistically significan.

Source: Khosrow-Khavar F, Kim SC, Lee H , et a.

Khosrow-Khavar F, Kim SC, Lee H , et a.
Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) stu.
Annals of the Rheumatic Diseases2022; 81: 798-80 , et al Annals of the Rheumatic Diseases81: leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

High Purity 99% BPN14770 Zatolmilast 1606974-33-7 In Stock Fast Ship to USA

CAS No.: 1606974-33-7

Pharm Grade

$1-1.1/UNIT FOB

High quality Thymosin α1 Pure CAS 62304-98-7 Thymosin Alpha 1 Thymalfasin

CAS No.: 62304-98-7

Pharmacy Grade

$12-15/UNIT FOB

Top quantity Imiquimod CAS NO 99011-02-6 White crystalline powder 99% API

CAS No.: 99011-02-6

Pharmacy Grade

$1800-1850/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.